Michael Powell
CIK 1202793 · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VERA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MENLO PARK, CA 94025
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCAX | Director | — | $16.89 | — | $0 | 2 | 2026-06-10 |
| Galera Therapeutics, Inc. (GRTX) Delisted | Director | — | $17.60 | — | $0 | 5 | 2023-06-16 |
| Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | Director | — | $10.50 | — | $0 | 4 | 2022-05-31 |
| VERA | 10%+ Owner | 2,187,504 | $28.30 | $61.91M | $32.00M | 1 | 2021-05-18 |
| NXTC | 10%+ Owner | 222,655 | $5.22 | $1.16M | $27.56M | 1 | 2019-11-19 |
| SYNLOGIC, INC. (SYBX) Delisted | Director | 38,331 | $0.69 | $26.4K | $0 | 5 | 2019-06-07 |
| Iterum Therapeutics plc (ITRM) Delisted | 10%+ Owner | 81,768 | $0.03 | $2.5K | $26.00M | 1 | 2018-05-30 |
| SYNLOGIC, INC. (MIRN) Delisted | Director | 2,117,669 | — | — | $6.00M | 2 | 2016-09-06 |
| HUMANIGEN, INC (KBIO) Delisted | 10%+ Owner | 39,637 | — | — | $0 | 1 | 2013-02-07 |
| Trius Therapeutics Inc (TSRX) Delisted | Director | 9,302 | — | — | $3.98M | 7 | 2012-03-27 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | 10%+ Owner | 51,542 | — | — | -$1.09M | 1 | 2012-01-03 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | Director | 3,236 | — | — | -$22.41M | 13 | 2011-06-06 |
| Molecular Templates, Inc. (THLD) Delisted | Director | — | — | — | $0 | 2 | 2008-05-14 |
| ANESIVA, INC. (ANSV) Delisted | Director | 3,703,769 | — | — | $15.00M | 5 | 2008-05-12 |
Recent Filings · Page 3 of 6
58 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-09-06 | SYNLOGIC, INC. (MIRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-07-13 | — | Exer (M) | +11,969 | $15.1K | |
| 2016-06-15 | — | Grant (A) | — | $0 | |
| 2015-10-06 | SYNLOGIC, INC. (MIRN) Delisted | Mixed | +2,974,811 | $6.00M | EDGAR |
| 2015-09-30 | — | Grant (A) | — | $0 | |
| 2015-06-22 | — | Grant (A) | — | $0 | |
| 2014-03-20 | — | Other (J) | −410,022 | $0 | |
| 2013-12-23 | — | Grant (A) | — | $0 | |
| 2013-07-17 | — | Mixed | +1,242,492 | $2.36M | |
| 2013-02-07 | HUMANIGEN, INC (KBIO) Delisted | Conv (C) | +12,355,819 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.